Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS
about
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaCost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsCost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United StatesRoutine HIV screening in Portugal: clinical impact and cost-effectiveness.Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United StatesThe cost and incidence of prescribing errors among privately insured HIV patients.Health-Related Quality of Life in HIV-Infected and At-Risk Women: The Impact of Illicit Drug Use and Hepatitis C on a Community Preference Weighted Measure.A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical triThe impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá.Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.Prediction of health preference values from CD4 counts in individuals with HIV.Psoriasis uncovered--measuring burden of disease impact in a survey of Australians with psoriasis.Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa.Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.Utilities derived from visual analog scale scores in patients with HIV/AIDS.Health-state valuations have been core issues in the field of medical decision making.
P2860
Q33841718-544B4C5B-B803-4F64-8084-E47620361944Q34227450-92184A6F-32BC-4E7F-9456-6307BEB93905Q34606231-4A9A303A-4E64-473C-A189-3961656850C6Q34735072-73473E3F-A912-4D80-9D6E-59EFD1DCF22AQ35058786-E60D312B-9DA1-4864-A452-0A396AC13544Q35075697-37ABBF36-C9C2-4D79-9D03-3DEA6FC255A6Q36205807-86C92060-7495-48A0-8AED-5BF5658D62EFQ36402466-3DEA68FD-890E-4230-A24D-0349C2B64CF8Q37656198-3F24D377-1675-4D83-AD3B-11D36524AD90Q37693067-01A14F65-318A-4571-A644-BD6F6BE6D79FQ38541022-B5FF8354-AA88-43F3-80FA-F5CF5C58B73DQ38673571-A1D8B8E5-21D8-4E92-A9AF-0C0208F72070Q40215329-6999DC52-D6C9-4315-96A2-E2844B702989Q40509615-720E7610-7E7C-45B2-B6C3-0EAAC99515B3Q40891018-DDE05B26-CB21-420E-933E-F83541DF2741Q42245563-01B0AC0B-09CE-4476-B805-26D7437E8A46Q42772430-0F7FD9C2-5DAF-437D-ABB6-35CA98799141Q42772436-0D3DDC99-983A-4DDE-A093-12AAA1896557Q42772440-0E566ED6-71DB-4739-86E1-730D932D171DQ43027648-43041C4E-F495-4C99-AE78-397DD00ED39DQ43431767-532D877D-2614-465B-8BA0-4618D2B540FAQ43720323-7A636813-AE45-439C-BA7D-31A1C714D4B6Q44887677-75EBD3D5-AEB4-4855-A436-653D5ECB7E53Q46302284-19006774-D912-4DFA-87B2-5A3E68A300B8Q46407326-677FB2FD-8F4D-4457-B3CB-99B95F656CC2Q47431983-A52B3DA9-6C9B-41BE-A029-8F7C00146DB9Q52006550-C77B6777-1793-47E9-9CD8-F075B0E20404
P2860
Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS
description
article
@en
im Februar 2002 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2002
@uk
name
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@en
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@nl
type
label
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@en
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@nl
prefLabel
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@en
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@nl
P2860
P50
P1476
Comparison of Health State Uti ...... rvey of Patients with HIV/AIDS
@en
P2093
Bruce R. Schackman
John Brazier
P2860
P356
10.1177/0272989X0202200103
P577
2002-02-01T00:00:00Z